Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

neoplasms/phosphatase

Povezava se shrani v odložišče
Stran 1 iz 303 rezultatov

Northeast COVID-19 and Pregnancy Study Group

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
General Objective: To determine the frequency of COVID-19 in pregnant and postpartum women admitted with flu syndrome, to evaluate the clinical and laboratory predictors of COVID-19 progression and to identify the factors associated with adverse maternal and perinatal / neonatal outcomes in six

Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Study design and participants The current prospective cohort study has been conducted with 73 patients of both sexes, with recently diagnosed benign and malignant respiratory diseases recruited from Cardio-Thoracic Surgery and Oncology Departments, Qena University Hospitals, South Valley University,
Study design This clinical-laboratorial, paralel, randomized, prospective and controlled study will be determine the impact of of PTFE-d barrier intentionally exposed to bucal environment in guided bone regeneration to ridge preservation, using microbiological, radiographic, patient-centered

Correlation Between MLR and Risk of Death and Cardiovascular Events in PD Patients.

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The epidemiological survey of chronic kidney disease in China shows that the current incidence of chronic kidney disease (CKD) in China is about 10.8%, with about 119 million patients. About 2% of patients will enter the stage of end-stage renal disease (ESRD) and require dialysis or kidney

Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. The aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (SRP) and SRP in conjunction with injectable
1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology 2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated

Thyroid Cancer and (FDG)PET/CT Scan

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Design and Methodology Study design:- It's a prospective study for the group of patients who will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels. Pre-study investigations:- - All patients at this study should have

Pirfenidone and Advanced Liver Fibrosis.

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol was approved by local Institutional Review Board and registered in clinical trials.gov. Clinical and Laboratory Evaluation Blood counts and liver
PRIMARY OBJECTIVE: I. To determine if the combination of radium Ra 223 dichloride (radium-223 dichloride) and paclitaxel improves progression-free survival (PFS) compared to paclitaxel alone. SECONDARY OBJECTIVES: I. To determine the time to the first symptomatic skeletal event [SSE] (defined as 1st
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of nedisertib (M3814) in combination with radium-223 dichloride or in combination with radium-223 dichloride and avelumab in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC) based on dose limiting
PRIMARY OBJECTIVE: I. To assess the symptomatic skeletal event (SSE)-free survival of metastatic renal cell cancer (mRCC) patients with bone metastases treated with cabozantinib S-malate (cabozantinib) + radium Ra 223 dichloride (radium-223 dichloride) compared to cabozantinib alone. SECONDARY

Empirical Antibiotics in Acute Inflammatory Gallbladder Disease

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
1. Background In the case of acute cholecystitis, in which acute inflammation was manifested in patients with gallstones and was accompanied by pain and fever, cholecystectomy through surgery was the standard treatment, and the use of empirical antibiotics to treat inflammation and prevent

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The Phase I part of this study will perform a dose-escalation to identify the recommended Phase II dose of LAE001/prednisone plus afuresertib in m-CRPC patients. In the Phase II part of this study, the anti-tumor efficacy of LAE001/prednisone plus afuresertib and of afuresertib alone will be

Utility of Primary Glioblastoma Cell Lines

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Glioblastoma (GBM) is the most aggressive type of brain tumor arising from glial cells accounting for 52% of all parenchymal brain cancer cases and 20% of all intracranial tumors. GBM has pronounced mitotic activity, substantial tendency toward neoangiogenesis (microvascular proliferation),

Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
OUTLINE: Patients are randomized to 1 of 3 arms. Arm I: Patients receive binimetinib orally (PO) twice daily (BID) for a lead-in period of 15 days in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib orally (PO) twice daily (BID) on days 1-28 and avelumab
Pridružite se naši
facebook strani

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

  • Deluje v 55 jezikih
  • Zeliščna zdravila, podprta z znanostjo
  • Prepoznavanje zelišč po sliki
  • Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
  • Preberite znanstvene publikacije, povezane z vašim iskanjem
  • Iščite zdravilna zelišča po njihovih učinkih
  • Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah

Google Play badgeApp Store badge